Vernal Biosciences
High purity mRNA from concept to clinical trials.
High purity mRNA from concept to clinical trials.
Vernal Biosciences is a biotechnology startup founded in 2021 with the slogan "High purity mRNA from concept to clinical trials." The company, headquartered in the United States, is a Contract Development and Manufacturing Organization (CDMO) that aims to make mRNA more accessible by prioritizing quality in the manufacturing process. In June 27, 2023, Vernal Biosciences secured a significant $20.00M Series A investment led by Dynamk Capital, Ampersand Capital Partners, Vermont Center for Emerging Technologies, and Charles River Laboratories International. This strategic funding is poised to enable Vernal Biosciences to achieve considerable milestones and further advance its position as a leader in mRNA manufacturing for various applications, including clinical trials.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $20.00M | 4 |
|
27 Jun 2023 |
| Series A | $21.00M | 5 |
|
02 Jun 2022 |
| Seed Round | Unknown | 1 | Alloy Therapeutics | 12 Jul 2021 |
No recent news or press coverage available for Vernal Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
